ECM
BLPH

Element Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Element Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-11,646
Closed -$60K – 95
2021
Q1 		$60K Buy
+11,646
New +$81.1K 0.01% 52

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Element Capital Management's BLPH Position: Q2 2021 in Review

Element Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 11,646 shares — an estimated $60K sold.

Element Capital Management first reported a position in BLPH in Q1 2021 and held it in 1 quarter. The position peaked at $60K in Q1 2021. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • Element Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Element Capital Management sold 11,646 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $60K.
  • Element Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Element Capital Management's Bellerophon Therapeutics, Inc. position peaked at $60K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Element Capital Management's 13F filing for Q2 2021, filed 11 Aug 2021.